Twist Bioscience Corp reported fiscal second quarter 2026 results: revenue $110.7 million, net income $44.0 million, EPS $0.71 per share. Guidance raised.
“expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results — Record revenue of $110.7 million in 2QFY26 ; Increase of more than 19% over $92.8 million in 2QFY25; 13th consecutive quarter of sequential growth — — Gross margin of 51.6% in 2QFY26 ; Improvement of”
Earnings Releases
Twist Bioscience Corp reported fiscal year 2024 results: revenue $300M to $304M. Guidance raised.
“— Increased FY 2024 revenue guidance to a range of $300M to $304M; Increased FY 2024 gross margin guidance to a range of 41.5 to 42.0% —”
Earnings Releases
Twist Bioscience Corp reported fiscal second quarter ended March 31, 2024 results: revenue $75.3 million, net income -$45.5 million, EPS -$0.79.
“FISCAL 2024 SECOND QUARTER FINANCIAL RESULTS • Orders: Total orders received for the second quarter of fiscal 2024 increased to $93.2 million compared to $64.2 million for the same period of fiscal 2023 . • Revenue: Total revenues for the second quarter of fiscal 2024 increased to $75.3 million compared to $60.2 million for the same period of fiscal 2023 . ◦ SynBio revenue increased to $29.8 million for the second quarter of fiscal 2024 compared to $24.2 million for the same period of fiscal 2023. ◦ NGS revenue increased to $40.8 million for the second quarter of fiscal 2024 compared to $29.0 million for the same period of fiscal 2023. ◦ Biopharma revenue was $4.7 million for the second quarter of fiscal 2024 compared to $7.0 million in the same period of fiscal 2023. • Cost of Revenues: Cost of revenues for the second quarter of fiscal 2024 was $44.4 million compared to $41.7 million for the same period of fiscal 2023 . • Gross Margin: Gross margin for the second quarter of fiscal 202”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.